ADG116 in Patients With Advanced/Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, dose escalation study in patients with advanced/metastatic
solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that
specifically binds to human CTLA-4. ADG 116 administered intravenously (IV) over a period of
60-90 minutes. The study is planned to treat up to 60 patients.